Histological evaluation of sinus augmentation using platelet rich plasma (PRP): a case series.
The use of Platelet Rich Plasma (PRP) in conjunction with autogenous bone graft materials has recently been advocated for use in sinus augmentation surgery as a means of enhancing both quantity and quality of newly forming bone. The use of PRP is based on the premise that autogenous plasma, rich in platelets, contributes large quantities of mitogenic polypeptides such as Platelet Derived Growth Factor (PDGF), Transforming Growth Factor-b (TGF-b) and Insulin-like Growth Factor-I (IGF-I), thereby enhancing osteogenesis. The aim of this study was to evaluate the potential of PRP to enhance bone formation following sinus augmentation with different bone derivative/substitute materials (DFDBA, FDBA, Xenograft, Bioactive Glass). This study presents histology of trephine-obtained core samples from five clinical cases in which sinus augmentation was performed with PRP combined with bone derivatives/substitutes. Histological evaluation of this case series consistently revealed the presence of residual graft particles surrounded by loose connective tissue, with a limited amount of newly formed bone. The findings suggest that the addition of PRP to bone derivative/substitute materials may not significantly enhance bone formation in the maxillary sinus area.
Danesh-Meyer
M J
MJ
Department of Periodontology, Temple University, School of Dentistry, Philadelphia, PA, USA. IDIP@xtra.co.nz
Filstein
M R
MR
Shanaman
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D001672:Biocompatible Materials / Q000627:therapeutic use; D001706:Biopsy; D001792:Blood Platelets / Q000502:physiology; D001857:Bone Matrix / Q000473:pathology; D018786:Bone Substitutes / Q000627:therapeutic use; D016025:Bone Transplantation; D002516:Ceramics / Q000627:therapeutic use; D003238:Connective Tissue / Q000473:pathology; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D008297:Male; D008437:Maxilla / Q000473:pathology / Q000601:surgery*; D008443:Maxillary Sinus / Q000473:pathology / Q000601:surgery*; D008567:Membranes, Artificial; D008875:Middle Aged; D010012:Osteogenesis / Q000502:physiology; D017713:Platelet Transfusion; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous; D014945:Wound Healing
D001672:Biocompatible Materials; C022107:Bioglass; D018786:Bone Substitutes; D008567:Membranes, Artificial; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D007334:Insulin-Like Growth Factor I